Skip to main content
SpringerPlus

Table 3 Results of the multivariable analysis of variables affecting progression free and overall survival

From: Prognostic significance of platelet–lymphocyte ratio in patients receiving first-line tyrosine kinase inhibitors for metastatic renal cell cancer

 

Progression free survival

Overall survival

HR

p value

HR

p value

ECOG PS (≥2)

  

3.60 (1.39–9.31)

0.008

Lymph node metastasis

  

2.76 (1.11–6.86)

0.029

Brain metastasis

4.94 (1.75–13.9)

0.002

9.39 (2.74–32.1)

0.001

Platelet–lymphocyte ratio (>150)

13.1 (5.14–33.2)

0.001

16.1 (4.4–58.4)

0.001

  1. ECOG PS Eastern cooperative oncology group performance status, HR Hazard ratio
Back to article page